HEALING IN EVERY DROP
TM
Eluciderm will
Improve the Lives of Billions Worldwide
Be a
SuperHealer
TM
Beneath every scar, within every wound, lies an innate regenerative capacity waiting to be activated. At Eluciderm, we harness this untapped biological potential, unlocking embryonic pathways to heal not just faster, but better through true tissue regeneration.
Eluciderm is revolutionizing regenerative medicine with therapeutics that enhance wound healing and minimize scarring after trauma. Eluciderm has created novel, safe, and highly effective topically applied compounds for the treatment of wounds and burns to regenerate fully functional skin and cartilage. Healing time is faster and the repaired skin has superior tensile strength and elasticity, while dramatically reducing the formation of scar tissue.
Safe
Topical
Point-of-Care
Skin Regeneration
Anywhere / Anytime
Eluciderm’s compounds can be applied topically, taking treatment out of the hospital and allowing people to use it anywhere and anytime. Imagine being able to apply this life-changing therapy to burn victims at the scene of the fire, or even to injured astronauts in space.
Our patented lead therapeutic candidate, ELU42, stands apart from injection-based therapeutics by being easier to administer, safer, and cheaper.
Be a SuperHealer
TM
Rapid Regenerative
Healing with Reduced Scars
Our novel therapeutic prompts the regenerative healing of damaged skin and cartilage so that tissues return to their normal structure without the functional and aesthetic impairments associated with scarring (fibrosis).
Eluciderm’s breakthrough therapy accelerates wound closure, restores full skin function—including dermal appendages—and replicates natural collagen architecture to prevent rigid scar formation, ensuring true regenerative healing.
​
Imagine:
-
the freedom from the need to hide or feel ashamed behind disfigurement reduced suffering as a consequence of poorly healed and devastating wounds, burns and scars
-
reduced suffering from poorly healed and devastating wounds, burns and scars
-
the rise in global confidence when the trauma of living with disfiguring scars is reduced
​
Eluciderm’s Platform
of Small Molecules:
The field of regenerative medicine is reaching a defining moment and Eluciderm is leading the charge. With unmatched scientific validation, a world-class team, and robust patent protection. Our first-in-class topical small molecule platform is revolutionizing wound care, bridging science and nature to create safe, non-invasive treatments that go beyond conventional healing. Eluciderm products reawaken the body's regenerative blueprint, suppressing fibrosis, accelerating recovery, and fostering new tissue growth, all within a bacteriostatic healing environment.
Eluciderm, Inc.
Winner of the
WHS WoundShark
Innovation Award
at SAWC 2024
for ELU42
Winner
WHS Woundshark 2024 INNOVATION AWARD
ELU42
Eluciderm's Patented
Lead Therapeutic Candidate
TM
​Judges recognized ELU42, a groundbreaking topical small-molecule drug for its potential to revolutionize wound care and deliver major market impact by accelerating healing of diabetic ulcers, third-degree burns, and open traumatic wounds. Third-degree burn victims will regenerate functional skin with reduced infection and scarring. Trauma victims, including blast injury patients, will heal more rapidly with reduced infection and scaring. Surgery patients with open wounds will heal faster with stronger and yet more elastic skin, minimal scarring, and reduced infection. Diabetics and other patients with chronic open wounds will experience regenerative wound healing and tissue regrowth with less infection and fewer complications.
3 Breakthroughs
Behind Eluciderm
Our first breakthrough came from the insight that our skin cells innate cellular instructions for regenerative healing can be reactivated through the topical addition of our Wnt modulator.
Cellular Intelligence
TM
Our discovery taps into the skin's dormant innate regenerative repair program, unlocking molecular driven cellular "cross-talk" to orchestrate accelerated functional healing with tissue regeneration.
Cellular Communication
Patent on Topical Application
of ELU42
Our third breakthrough was securing the patent for topical application of ELU42. With both FDA Investigational New Drug (IND) and broad patent coverage, ELU42 offers a valuable novel approach to acute and chronic open wound curative treatment across many untapped markets worth tens of billions of dollars annually.
Untapped Markets
Massive Opportunity
There are currently no FDA-approved scar prevention therapies available. Also, there are no cost effective and simple to administer drug therapies available to treat chronic wounds. Each unmet medical need represents a massive market opportunity.
Wound Types & Markets
2020: >$1B
Osteoarthritis
(cartilage regeneration)
Chronic Wounds
2014: $96B
Traumatic Open Soft Tissue Wounds
$34.5 million nationally
$237 million worldwide
$4.8B Global cartilage repair market in 2018
Scar Treatments
2017: $19B
2023: (predicted) $32B
Cosmetic Surgeries
Global $50B by 2027
A Rare Opportunity to Impact Healing Around
the World
Eluciderm intends to capture as much of these available markets through an aggressive intellectual property strategy, by filing multiple compositions of matter and method of use patents for Eluciderm therapeutics.
We intend to take our recently patented lead molecule (ELU42) into human trials for three indications: diabetic foot ulcers, burns, and open soft tissue wounds.
Eluciderm Team
Daniel Holsworth, PhD, RAC (CEO)
Dr. Dan Holsworth is the Chief Executive Officer and founder of Eluciderm Inc. He is an entrepreneur, medicinal chemist and expert in the field of drug discovery with over 30 years of experience, including multiple stints in senior level research and director positions in the Biotech and Pharma industries, most notably Amylin Pharmaceuticals and Pfizer Global Research & Development. His research projects over the years have focused on a variety of therapeutic areas ranging from oncology, cardiovascular, metabolic, and inflammation, to more recent efforts in the fields of dermatology, and wound healing. His work has culminated in over half a dozen clinical candidates. He is the inventor on 40 patents and author of over 100 publications, book chapters, and presentations. Dr. Holsworth earned his doctorate in synthetic organic chemistry from Wayne State University in Detroit, Michigan, and was a Post-Doctoral Fellow in Medicinal Chemistry at Parke-Davis Pharmaceuticals in Ann Arbor, Michigan.
Sarika Saraswati, PhD (CSO)
Dr. Sarika Saraswati is the Chief Scientific Officer at Eluciderm Inc. She has more than 15 years of experience in studying biochemical and cellular aspects of human disease conditions that includes stem cells, regenerative medicine, wound healing and fibrosis. Currently, Dr. Saraswati also serves as a tenure track Assistant Professor at Tennessee State University with an adjunct appointment at Vanderbilt University Medical Center. Her research has been continuously funded by National Institute of Health, American Association of Blood Banks, and American Heart Association in addition to Internal grants at Vanderbilt. Dr. Saraswati has received multiple honors and awards including Young Investigator Award at the International Innovations in Wound Healing Conference and multiple first place awards in oral/poster presentation at International and National Conferences. Dr. Saraswati earned her Doctorate in Biochemistry and Molecular Biology from University of Arkansas for Medical Sciences, Little Rock, AR and her post-doctoral training at Vanderbilt University Medical Center, Nashville, TN.
John P. Delgado, MD, FAAFP (CMO)
John P. Delgado, MD is the Chief Medical Officer and co-founder of Eluciderm, Inc. He has over 35 years of both research and clinical experience in the areas of Clinical Research, Family Medicine, obstetrics, functional medicine, Stem Cell and Regenerative Medicine, procedural medicine, sports medicine and health administration. He has served as the Medical Director and Principle Investigator at Velocity Clinical Research in both Grants Pass and Medford, Oregon. Additionally, Dr. Delgado has served as Chief of Obstetrics and Perinatology in Ashland, Oregon, and has been the principle investigator in over 250 clinical studies, including major studies with Harvard University, the Cleveland Clinic, Mayo Clinic and several other private organizations.
Dr. Delgado earned a Bachelor degree in Biological Sciences at Stanford University, attended UCLA Medical School, and is Board Certified in Family Medicine with memberships in the Institute of Functional Medicine and the American Academy of Stem Cell Physicians.
Joseph Marino (CBO)
Joseph Marino serves as a Chief Business Officer and co-founder of Eluciderm, Inc. For the past 40+ years he has embodied the entrepreneurial spirit with an unmatched series of startup-to-sale successes in the alternative/renewable/sustainable energy sector. His unique abilities as CEO/President to identify market potential and juggle both technical & leadership responsibilities have allowed him to repeatedly create forward-thinking products, build dynamic teams, and develop lucrative market segments. To date he has launched and sold four energy-based companies, and he continues to run a fifth. Always on the lookout for a new challenge, in 2020 Mr. Marino jumped at the opportunity to help Eluciderm navigate the business side of the biotech/pharmaceutical world. In addition to more technical pursuits, Mr. Marino is also an avid real estate investor; the crown jewel of his portfolio is the historic Noyo Harbor Inn, a 152-year-old boutique establishment on the stunning Mendocino Coast.
John J. Cummings III JD
Seed Investor
Board Member
Prominent former New Orleans-based trial lawyer and highly accomplished investor, Mr. Cummings now devotes much of his time and resources to philanthropic endeavors and the implementation of effective corporate strategy for Eluciderm.
Clinical Advisory Board
Clinical Advisory Board
Scientific Advisory Board
Legal
Intellectual Property: Squire Patton Boggs LLP
Corporate: Morrison Foerster LLP
Eluciderm Board
John J. Cummings III JD (Seed Investor)
​
Daniel Holsworth,
PhD, RAC (CEO)
John P. Delgado,
MD, FAAFP (CMO)
Joseph Marino
(CBO)
Dr. Dan Holsworth is the Chief Executive Officer and founder of Eluciderm Inc. He is an entrepreneur, medicinal chemist and expert in the field of drug discovery with over 30 years of experience, including multiple stints in senior level research and director positions in the Biotech and Pharma industries, most notably Amylin Pharmaceuticals and Pfizer Global Research & Development. His research projects over the years have focused on a variety of therapeutic areas ranging from oncology, cardiovascular, metabolic, and inflammation, to more recent efforts in the fields of dermatology, and wound healing. His work has culminated in over half a dozen clinical candidates. He is the inventor on 40 patents and author of over 100 publications, book chapters, and presentations. Dr. Holsworth earned his doctorate in synthetic organic chemistry from Wayne State University in Detroit, Michigan, and was a Post-Doctoral Fellow in Medicinal Chemistry at Parke-Davis Pharmaceuticals in Ann Arbor, Michigan.
Dr. John Delgado is the Chief Medical Officer and a co-founder of Eluciderm, Inc. He has over 30 years of research and clinical experience and has served as Principal Investigator in hundreds of clinical studies in partnership with Harvard University, the Cleveland Clinic, the Mayo Clinic, and numerous private organizations. He has served as Medical Director and Principal Investigator at Velocity Clinical Research in Oregon. Dr. Delgado earned his bachelor's at Stanford University and his M.D. at UCLA.
Joseph Marino serves as a Chief Business Officer and co-founder of Eluciderm, Inc. For the past 40+ years he has embodied the entrepreneurial spirit with an unmatched series of startup-to-sale successes in the alternative/renewable/sustainable energy sector. His unique abilities as CEO/President to identify market potential and juggle both technical & leadership responsibilities have allowed him to repeatedly create forward-thinking products, build dynamic teams, and develop lucrative market segments. To date he has launched and sold four energy-based companies, and he continues to run a fifth. Always on the lookout for a new challenge, in 2020 Mr. Marino jumped at the opportunity to help Eluciderm navigate the business side of the biotech/pharmaceutical world. In addition to more technical pursuits, Mr. Marino is also an avid real estate investor; the crown jewel of his portfolio is the historic Noyo Harbor Inn, a 152-year-old boutique establishment on the stunning Mendocino Coast.
Prominent former New Orleans-based trial lawyer and highly accomplished investor, Mr. Cummings now devotes much of his time and resources to philanthropic endeavors and the implementation of effective corporate strategy for Eluciderm.
Contact: Dan Holsworth, PhD, RAC
Founder & CEO, Eluciderm Inc.
San Diego, CA. USA
